BIOGAIA AB B O.N.
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more
BIOGAIA AB B O.N. (BGLA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOGAIA AB B O.N. (BGLA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOGAIA AB B O.N. - Net Assets Trend (None–None)
This chart illustrates how BIOGAIA AB B O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOGAIA AB B O.N. (None–None)
The table below shows the annual net assets of BIOGAIA AB B O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOGAIA AB B O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOGAIA AB B O.N. Competitors by Market Cap
The table below lists competitors of BIOGAIA AB B O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank of Xi'An Co Ltd
SHG:600928
|
$760.37 Million |
|
Garden Reach Shipbuilders & Engineers Limited
NSE:GRSE
|
$760.61 Million |
|
PT Bumi Resources Tbk
PINK:PBMRF
|
$760.82 Million |
|
Collective Mining Ltd.
NYSE:CNL
|
$761.19 Million |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
$759.87 Million |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
$759.76 Million |
|
Shandong Kaisheng New Materials Co.Ltd.
SHE:301069
|
$759.65 Million |
|
HJ ShipBuilding & Construction Co Ltd
KO:097230
|
$759.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOGAIA AB B O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOGAIA AB B O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOGAIA AB B O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOGAIA AB B O.N.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOGAIA AB B O.N. (BGLA) | €- | N/A | N/A | $760.05 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |